Christian Rosker
About Christian Rosker
Christian Rosker is the Disease Area Head Oncology at Bristol-Myers Squibb, with a background in pharmacology and extensive experience in medical and scientific roles across Europe and the United States.
Company
Christian Rosker is currently employed by Bristol-Myers Squibb, a global biopharmaceutical company. Holding the position of Disease Area Head Oncology, he is based in New Jersey, United States. Since joining in September 2017, Rosker has been steering the direction of the oncology disease area within the company.
Title
Christian Rosker holds the title of Disease Area Head Oncology at Bristol-Myers Squibb. In this role, he oversees oncology research and development, aiming to address various cancer types through innovative therapeutic solutions.
Education and Expertise
Christian Rosker studied Pharmacology at Karl-Franzens-Universität Graz, completing his studies over three years, from 2002 to 2005. He has a rich academic and professional background, having undertaken a postdoctoral fellowship at the Medical University of Graz and contributing to research as a Research Associate at the University of Cambridge.
Work History
Christian Rosker's extensive work history includes roles at prominent institutions and pharmaceutical companies. He served as a Medical Manager for Rare Diseases at Sanofi Genzyme from 2013 to 2014 and held the position of MSL Head Austria and Med Director SMA EU at Biogen from 2014 to 2015. Additionally, Rosker was employed as a Medical Scientific Liaison Manager at Novartis from 2011 to 2012. His experience also includes academic roles, such as serving as a University Assistant at Universität Bern from 2008 to 2011 and as a Research Associate at the University of Cambridge from 2007 to 2008.
Background
Christian Rosker's background is rooted in both academic research and the pharmaceutical industry. His roles have taken him across various countries, including Switzerland, the United Kingdom, and the United States. Throughout his career, he has focused on areas such as oncology and rare diseases, building a diverse portfolio of expertise.